The American Society of Hemophilia (ASH) released information about their upcoming 57th ASH Annual Meeting, which will be held December 5-8, 2015 in Orlando, Florida. Included in the program information is a paper abstract about the SIPPET study (Survey of Inhibitors in Plasma-Product Exposed Toddlers.)Â A plenary session with further information will be presented at the ASH Annual Meeting.
The purpose of the investigator-driven, multicenter, open label, randomizedÂ study was to compare the incidence of factor VIII (FVIII)Â inhibitors with plasma-derived FVIII concentrates versus recombinant FVIII concentrates in previously untreated patients (PUPs) with severe hemophilia.
The conclusion of the abstract reads, “The rFVIII product class was associated with a 1.87-fold higher incidence of inhibitors than the plasma-derived FVIIIÂ class.” This difference remained even when second generation full lengthÂ rFVIIIÂ concentrate was excluded from the analyses. The results of this randomized study have implications in the choice of product for management of PUPs, as inhibitor development remains a major challenge in the management of haemophilia A.
HFA is following this study and will help to bring the community more information as it becomes available.